252 related articles for article (PubMed ID: 34287682)
1. Thiopurine pharmacogenomics and pregnancy in inflammatory bowel disease.
Andoh A; Kawahara M; Imai T; Tatsumi G; Inatomi O; Kakuta Y
J Gastroenterol; 2021 Oct; 56(10):881-890. PubMed ID: 34287682
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
Kakuta Y; Kinouchi Y; Shimosegawa T
J Gastroenterol; 2018 Feb; 53(2):172-180. PubMed ID: 29192347
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
[TBL] [Abstract][Full Text] [Related]
4. Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review.
Desai D; Jena A; Sharma V; Hibi T
Expert Rev Clin Pharmacol; 2023; 16(7):643-653. PubMed ID: 37387532
[TBL] [Abstract][Full Text] [Related]
5. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Kakuta Y; Kawai Y; Okamoto D; Takagawa T; Ikeya K; Sakuraba H; Nishida A; Nakagawa S; Miura M; Toyonaga T; Onodera K; Shinozaki M; Ishiguro Y; Mizuno S; Takahara M; Yanai S; Hokari R; Nakagawa T; Araki H; Motoya S; Naito T; Moroi R; Shiga H; Endo K; Kobayashi T; Naganuma M; Hiraoka S; Matsumoto T; Nakamura S; Nakase H; Hisamatsu T; Sasaki M; Hanai H; Andoh A; Nagasaki M; Kinouchi Y; Shimosegawa T; Masamune A; Suzuki Y;
J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine.
Akiyama S; Matsuoka K; Fukuda K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Motobayashi M; Suzuki K; Takenaka K; Fujii T; Saito E; Nagahori M; Ohtsuka K; Mochizuki M; Watanabe M; Hashiguchi M; Kanai T
J Gastroenterol Hepatol; 2019 Oct; 34(10):1751-1757. PubMed ID: 31045285
[TBL] [Abstract][Full Text] [Related]
7.
Sato T; Takagawa T; Kakuta Y; Nishio A; Kawai M; Kamikozuru K; Yokoyama Y; Kita Y; Miyazaki T; Iimuro M; Hida N; Hori K; Ikeuchi H; Nakamura S
Intest Res; 2017 Jul; 15(3):328-337. PubMed ID: 28670229
[TBL] [Abstract][Full Text] [Related]
8. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
[TBL] [Abstract][Full Text] [Related]
9. Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
Kreijne JE; de Veer RC; de Boer NK; Dijkstra G; West R; Moorsel SAW; de Jong DJ; van der Woude CJ; de Vries AC;
Aliment Pharmacol Ther; 2019 Aug; 50(4):407-415. PubMed ID: 31359480
[TBL] [Abstract][Full Text] [Related]
10. Antenatal thiopurine exposure in women with IBD is associated with intrahepatic cholestasis of pregnancy.
Selinger CP; Rosiou K; Broglio G; Lever G; Chiu CM; Stocker LJ; Chipeta H; Glanville T
Expert Opin Drug Saf; 2023; 22(11):1091-1097. PubMed ID: 37417244
[TBL] [Abstract][Full Text] [Related]
11. Successful Pregnancies with Thiopurine-Allopurinol Co-Therapy for Inflammatory Bowel Disease.
Sheikh M; Nelson-Piercy C; Duley J; Florin T; Ansari A
J Crohns Colitis; 2015 Aug; 9(8):680-4. PubMed ID: 25939351
[TBL] [Abstract][Full Text] [Related]
12. Nudix hydrolase 15 (NUDT15) loss-of-function variants in an Australian inflammatory bowel disease population.
Afrin S; Simms LA; Lord A; Radford-Smith GL
Intern Med J; 2022 Nov; 52(11):1971-1977. PubMed ID: 35289057
[TBL] [Abstract][Full Text] [Related]
13. Loss of Nudt15 thiopurine detoxification increases direct DNA damage in hematopoietic stem cells.
Yamashita N; Kawahara M; Imai T; Tatsumi G; Asai-Nishishita A; Andoh A
Sci Rep; 2023 Jul; 13(1):11908. PubMed ID: 37488179
[TBL] [Abstract][Full Text] [Related]
14. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease.
Asada A; Nishida A; Shioya M; Imaeda H; Inatomi O; Bamba S; Kito K; Sugimoto M; Andoh A
J Gastroenterol; 2016 Jan; 51(1):22-9. PubMed ID: 26590936
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine Therapy for Inflammatory Bowel Disease During Pregnancy Is Not Associated with Anemia in the Infant.
Koslowsky B; Sadeh C; Grisaru-Granovsky S; Miskin H; Goldin E; Bar-Gil Shitrit A
Dig Dis Sci; 2019 Aug; 64(8):2286-2290. PubMed ID: 30815823
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Leong RW; Gearry RB; Sparrow MP
Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Hoentjen F; Seinen ML; Hanauer SB; de Boer NK; Rubin DT; Bouma G; Harrell LE; van Bodegraven AA
Inflamm Bowel Dis; 2013 Feb; 19(2):363-9. PubMed ID: 22605661
[TBL] [Abstract][Full Text] [Related]
18. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
Seinen ML; van Asseldonk DP; de Boer NK; Losekoot N; Smid K; Mulder CJ; Bouma G; Peters GJ; van Bodegraven AA
J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
[TBL] [Abstract][Full Text] [Related]
19. Thiopurine-mediated impairment of hematopoietic stem and leukemia cells in Nudt15
Tatsumi G; Kawahara M; Imai T; Nishishita-Asai A; Nishida A; Inatomi O; Yokoyama A; Kakuta Y; Kito K; Andoh A
Leukemia; 2020 Mar; 34(3):882-894. PubMed ID: 31645647
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).
Vasudevan A; Con D; De Cruz P; Sparrow MP; Friedman AB; Garg M; Kashkooli S; Gibson PR; van Langenberg DR
Aliment Pharmacol Ther; 2024 Feb; 59(4):504-514. PubMed ID: 38095246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
